Skip to main content

Using Live Patient-specific Tumor Tissue to Predict Therapeutic Response(s) in HGG Patients Before Treatment Initiation

High Grade Glioma (HGG) Functional Precision Medicine—A Six Webinar Series

Virtual 60-minute webinar featuring expert discussion of real world HGG patient cases.

SESSION 2 of 6

For this second installment of a six webinar series, join Dr. Mrugala of the Mayo Clinic, Arizona to hear how he is using live patient-specific tumor tissue to predict therapeutic response(s) in HGG patients before treatment initiation.

HGG patients have an extremely poor prognosis. Limited diagnostic tools are available to accurately predict treatment responses, leading to challenges in selecting effective therapeutic options. This interactive discussion features two real world clinical cases, presented by Dr. Maciej Mrugala of Mayo Clinic Phoenix, where a new functional precision oncology assay was used to direct therapy.

This Functional Precision Medicine Webinar Series is powered by OncoLens. On a single, secure platform, OncoLens data science, informatics and advanced collaboration tools provide a first of a kind platform for targeted treatment planning and confident clinical decision making.

Watch Session Cases Individually

Case #1 — 37 year-old female
Original Diagnosis (2008): Oligoastrocytoma, WHO grade II
Location: Right Frontal Region
5 Recurrences
Pathology (2023): high-grade astrocytoma
Molecular Markers: IDH mutant, high TMB & MSI

Case #2 — 33 year-old female
Diagnosis (2019): HGG, WHO Grade IV
Location: Right Parietal Region
Recurrence @2 years
Molecular Markers: BCOR alteration, MSI stable


Maciej M Mrugala, MD, PhD, MPH

Professor of Medicine and Neurology
Comprehensive Neuro-Oncology Program
Mayo Clinic, Phoenix, Arizona

High Grade Glioma (HGG) Functional Precision Medicine Webinar Series


Eric Perreault

Chief Business Officer

Tessa DesRochers, PhD

Chief Scientific Officer

Other Sessions